All In Biotech

Drug Trial Radar · NCT00489255

Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and Treatment

A Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Trimethobenzamide (Tigan®) in the Control of Nausea and Vomiting During Initiation and Continued Treatment With Subcutaneous Apomorphine (Apokyn®) in Apomorphine-naïve Subjects With Parkinson's Disease Suffering From Acute Intermittent "Off" Episodes, With Phased Withdrawal of Subjects From Tigan® to Placebo

Last checked: Nov 19, 2026Latest source record: Jan 30, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 117 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

117

Actual

Start

May 2007

Primary completion

Dec 2011

Study completion Mar 2012

Sponsor

Lead sponsor
IpsenIndustry
Sponsor type
Industry
Collaborators
INC Research Limited
First posted
Jun 21, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purposes of the study are to determine: i. To assess the efficacy of Tigan® (trimethobenzamide) in preventing nausea and vomiting when initiating therapy with Apokyn® (apomorphine) ii. To determine the optimal duration for continuation of Tigan® following initiation of Apokyn® therapy iii. To assess the safety of Tigan® in combination with Apokyn® iv. To characterize the pharmacokinetic (PK) profile of apomorphine in subjects treated concomitantly with and without Tigan®

Conditions

  • Parkinson's Disease

Interventions

  • Tigan®Drug

    Oral capsule, 300mg three times daily

  • PlaceboDrug

    Oral capsule, three times daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Nausea and/or Vomiting During the Initial Titration of Apokyn® at the Visit on Day 1Time frame: Day 1 (Period 1, Visit 2)

Locations

27 sites in 1 country. Site status is shown where the registry gives one.

  • Barrow Neurological Movement Disorder Clinic

    Phoenix, Arizona

  • Mayo Clinic

    Scottsdale, Arizona

  • Coastal Neurological Medical Group Inc.

    La Jolla, California

  • Neurosearch, Inc.

    Reseda, California

  • Neurosearch II, Inc.

    Ventura, California

  • Parkinson's Disease and Movement Disorders Center of Boca Raton

    Boca Raton, Florida

  • Neurology at Shands Medical Center

    Gainesville, Florida

  • University of Florida at Jacksonville

    Jacksonville, Florida

  • Neurology Associates of Ormond Beach

    Ormond Beach, Florida

  • Charlotte Neurological Services

    Port Charlotte, Florida

  • Suncoast Neuroscience Associates, Inc.

    St. Petersburg, Florida

  • USF Parkinson's Disease and Movement Disorders Center of Excellence

    Tampa, Florida

  • Emory University

    Atlanta, Georgia

  • NorthShore University Health System

    Glenview, Illinois

  • Iowa Health Physicians

    Des Moines, Iowa

  • Parkinson's & Movements Disorders Center of Maryland

    Elkridge, Maryland

  • Quest Research Institute

    Bingham Farms, Michigan

  • Henry Ford Health System - Franklin Point

    Southfield, Michigan

  • Parkinson's Disease and Movement Disorders Center of Long Island

    Commack, New York

  • Kingston Neurological Associates

    Kingston, New York

  • Raleigh Neurology Associates

    Raleigh, North Carolina

  • Neurological Institute, Cleveland Clinic

    Cleveland, Ohio

  • Neurology Specialist of Dallas P.A

    Dallas, Texas

  • Parkinson's Disease and Movement Disorders Center, Baylor College of Medicine

    Houston, Texas

  • Neurology Associates, P.A.

    San Antonio, Texas

  • East Texas Medical Center

    Tyler, Texas

  • Sentara Neurological Associates

    Virginia Beach, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.